# Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

> **NCT04439240** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (actual)

## Conditions studied

- Advanced Lymphoma
- Advanced Malignant Solid Neoplasm
- Hematopoietic and Lymphoid Cell Neoplasm
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** FGFR Inhibitor AZD4547

## Key facts

- **NCT ID:** NCT04439240
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2019-06-06
- **Final completion:** 2020-06-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439240, "Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04439240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*